C
Consolación Melguizo
Researcher at University of Granada
Publications - 132
Citations - 2994
Consolación Melguizo is an academic researcher from University of Granada. The author has contributed to research in topics: Cancer & Medicine. The author has an hindex of 23, co-authored 110 publications receiving 2070 citations. Previous affiliations of Consolación Melguizo include Andalusian Health Service.
Papers
More filters
Journal ArticleDOI
Lipid-Based Nanoparticles: Application and Recent Advances in Cancer Treatment.
Beatriz García-Pinel,Cristina Porras-Alcalá,Alicia Ortega-Rodríguez,Francisco Sarabia,Jose Prados,Consolación Melguizo,Juan Manuel López-Romero +6 more
TL;DR: The association of chemotherapeutic agents with lipid nanoparticles reduces active therapeutic dose and toxicity, decreases drug resistance and increases drug levels in tumor tissue by decreasing them in healthy tissue.
Journal ArticleDOI
Nanomedicine: Application Areas and Development Prospects
Houria Boulaiz,Pablo J. Álvarez,Alberto Ramírez,Juan A. Marchal,Jose Prados,Fernando Rodríguez-Serrano,Macarena Perán,Consolación Melguizo,Antonia Aránega +8 more
TL;DR: In nanomedicine, atoms and molecules are manipulated to produce nanostructures of the same size as biomolecules for interaction with human cells, offering a range of new solutions for diagnoses and “smart” treatments by stimulating the body’s own repair mechanisms.
Journal ArticleDOI
Temozolomide Resistance in Glioblastoma Cell Lines: Implication of MGMT, MMR, P-Glycoprotein and CD133 Expression.
Gloria Perazzoli,Jose Prados,Raúl Ortiz,Octavio Caba,Laura Cabeza,María Berdasco,Beatriz González,Consolación Melguizo +7 more
TL;DR: These results may be relevant in understanding the phenomenon of TMZ resistance, and may also aid in the design of new therapeutic strategies to improve the efficacy of TMZ in glioblastoma multiforme patients.
Journal ArticleDOI
Doxorubicin-Loaded Nanoparticles: New Advances in Breast Cancer Therapy
Jose Prados,Consolación Melguizo,Raúl Ortiz,Celia Vélez,Pablo J. Álvarez,José L. Arias,María Adolfina Ruiz,Visitación Gallardo,Antonia Aránega +8 more
TL;DR: An overview of doxorubicin nanoplatform-based delivery systems and the principal advances obtained in breast cancer chemotherapy is provided.
Journal ArticleDOI
Folic acid-decorated and PEGylated PLGA nanoparticles for improving the antitumour activity of 5-fluorouracil.
TL;DR: In vitro cytotoxicity studies in folate-overexpressed HT-29 colon cancer cells and MCF-7 breast cancer cells demonstrated that the half maximal inhibitory concentration (IC50) of 5-FU-loaded FOL-PEG-PLGA NPs was approximately 4-fold less than that of the 5-Fluorouracil-loaded PL GA NPs (p<0.05).